Cell therapy in chronic liver disease

Clara T. Nicolas, Yujia Wang, Scott Nyberg

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease. Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, because of their ready availability. Bioartificial liver devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells for the treatment of chronic liver disease holds promise. Bioartificial liver systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume32
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cell- and Tissue-Based Therapy
Liver Diseases
Hepatocytes
Cell Transplantation
Chronic Disease
Artificial Liver
Equipment and Supplies
Liver Transplantation
Stem Cells
Transplantation
End Stage Liver Disease
Regenerative Medicine
Liver
Liver Failure
Therapeutics
Mesenchymal Stromal Cells
Liver Cirrhosis
Adipose Tissue
Regeneration
Swine

Keywords

  • Bioartificial liver
  • Cell therapy
  • Chronic liver disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cell therapy in chronic liver disease. / Nicolas, Clara T.; Wang, Yujia; Nyberg, Scott.

In: Current Opinion in Gastroenterology, Vol. 32, No. 3, 01.01.2016, p. 189-194.

Research output: Contribution to journalReview article

Nicolas, Clara T. ; Wang, Yujia ; Nyberg, Scott. / Cell therapy in chronic liver disease. In: Current Opinion in Gastroenterology. 2016 ; Vol. 32, No. 3. pp. 189-194.
@article{6ff1324191e74e70b1e3ab8abe706f57,
title = "Cell therapy in chronic liver disease",
abstract = "Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease. Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, because of their ready availability. Bioartificial liver devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells for the treatment of chronic liver disease holds promise. Bioartificial liver systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.",
keywords = "Bioartificial liver, Cell therapy, Chronic liver disease",
author = "Nicolas, {Clara T.} and Yujia Wang and Scott Nyberg",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MOG.0000000000000262",
language = "English (US)",
volume = "32",
pages = "189--194",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cell therapy in chronic liver disease

AU - Nicolas, Clara T.

AU - Wang, Yujia

AU - Nyberg, Scott

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease. Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, because of their ready availability. Bioartificial liver devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells for the treatment of chronic liver disease holds promise. Bioartificial liver systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.

AB - Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease. Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, because of their ready availability. Bioartificial liver devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells for the treatment of chronic liver disease holds promise. Bioartificial liver systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.

KW - Bioartificial liver

KW - Cell therapy

KW - Chronic liver disease

UR - http://www.scopus.com/inward/record.url?scp=84960157704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960157704&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000262

DO - 10.1097/MOG.0000000000000262

M3 - Review article

VL - 32

SP - 189

EP - 194

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -